Literature DB >> 32145269

Different kinetics for the hepatic uptake of lipid nanoparticles between the apolipoprotein E/low density lipoprotein receptor and the N-acetyl-d-galactosamine/asialoglycoprotein receptor pathway.

Yusuke Sato1, Yoshiyuki Kinami2, Kazuki Hashiba2, Hideyoshi Harashima3.   

Abstract

Lipid nanoparticles (LNPs) are one of the more promising technologies for efficiently delivering nucleic acids in vivo. Hepatocytes are the primary target cells of LNPs that are delivered via the apolipoprotein E (ApoE)-low density lipoprotein receptor (LDLR) pathway, an endogenous targeting pathway. This robust targeting mechanism results in the specific and efficient delivery of nucleic acids to hepatocytes. Trivalent N-acetyl-D-galactosamine (GalNAc) is known to be a high-affinity exogenous ligand against the asialoglycoprotein receptor (ASGPR), which is highly expressed on hepatocytes. In this study, we report that the kinetics of the hepatic uptake process between the two types of targeting pathways are different. Rapid blood clearance, accumulation to the space of Disse and a subsequent slow cellular uptake was observed in the case of the endogenous ApoE-LDLR pathway. On the other hand, both blood clearance and cellular uptake were more gradual in the case of the exogenous GalNAc-ASGPR pathway. Interactions between ApoE-bound LNPs and hepatic heparan sulfate proteoglycans (HSPGs) were involved in the rapid blood clearance and accumulation to the space of Disse in the case of the endogenous pathway. The findings presented here contribute to a more precise understanding of the mechanism of hepatic uptake and to the rational design of hepatocyte-targeting nanoparticles.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apolipoprotein E; Asialoglycoprotein receptor; Heparansulfate proteoglycan; Hepatic uptake; Lipid nanoparticles; Low density lipoprotein receptor; N-acetyl-D-galactosamine

Mesh:

Substances:

Year:  2020        PMID: 32145269     DOI: 10.1016/j.jconrel.2020.03.006

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  12 in total

1.  Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis.

Authors:  Hossein Sendi; Mostafa Yazdimamaghani; Mengying Hu; Nikhila Sultanpuram; Jie Wang; Amber S Moody; Ellie McCabe; Jiajie Zhang; Amanda Graboski; Liantao Li; Juan D Rojas; Paul A Dayton; Leaf Huang; Andrew Z Wang
Journal:  Cancer Res       Date:  2021-11-09       Impact factor: 13.312

2.  Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line.

Authors:  Markus Aldén; Francisko Olofsson Falla; Daowei Yang; Mohammad Barghouth; Cheng Luan; Magnus Rasmussen; Yang De Marinis
Journal:  Curr Issues Mol Biol       Date:  2022-02-25       Impact factor: 2.976

Review 3.  Smart pH-responsive nanomedicines for disease therapy.

Authors:  Jongyoon Shinn; Nuri Kwon; Seon Ah Lee; Yonghyun Lee
Journal:  J Pharm Investig       Date:  2022-05-09

Review 4.  An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.

Authors:  Meng-Shi Li; Yang Li; Yang Liu; Xu-Jie Zhou; Hong Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-06

5.  Triantennary GalNAc-Functionalized Multi-Responsive Mesoporous Silica Nanoparticles for Drug Delivery Targeted at Asialoglycoprotein Receptor.

Authors:  Rosemeyre Cordeiro; Ana Carvalho; Luísa Durães; Henrique Faneca
Journal:  Int J Mol Sci       Date:  2022-06-02       Impact factor: 6.208

Review 6.  mRNA vaccine for cancer immunotherapy.

Authors:  Lei Miao; Yu Zhang; Leaf Huang
Journal:  Mol Cancer       Date:  2021-02-25       Impact factor: 27.401

Review 7.  Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics.

Authors:  Hidefumi Mukai; Koki Ogawa; Naoya Kato; Shigeru Kawakami
Journal:  Drug Metab Pharmacokinet       Date:  2022-02-05       Impact factor: 2.041

Review 8.  A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies.

Authors:  Monika Kumari; Ruei-Min Lu; Mu-Chun Li; Jhih-Liang Huang; Fu-Fei Hsu; Shih-Han Ko; Feng-Yi Ke; Shih-Chieh Su; Kang-Hao Liang; Joyce Pei-Yi Yuan; Hsiao-Ling Chiang; Cheng-Pu Sun; I-Jung Lee; Wen-Shan Li; Hsing-Pang Hsieh; Mi-Hua Tao; Han-Chung Wu
Journal:  J Biomed Sci       Date:  2022-09-12       Impact factor: 12.771

Review 9.  Evolution of drug delivery system from viewpoint of controlled intracellular trafficking and selective tissue targeting toward future nanomedicine.

Authors:  Yuma Yamada; Yusuke Sato; Takashi Nakamura; Hideyoshi Harashima
Journal:  J Control Release       Date:  2020-09-08       Impact factor: 9.776

Review 10.  Drug Targeting and Nanomedicine: Lessons Learned from Liver Targeting and Opportunities for Drug Innovation.

Authors:  Anna Salvati; Klaas Poelstra
Journal:  Pharmaceutics       Date:  2022-01-17       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.